Direct-to-consumer BRCA test vs clinical genetic testing: selected variants are not a full answer
An FDA-cleared direct-to-consumer report can test selected BRCA1 and BRCA2 variants, but it does not test every disease-causing variant or determine overall cancer risk. Clinical testing begins with personal and family history, purpose, appropriate genes and methods, confirmation, counseling, and follow-up.
A direct-to-consumer BRCA report can be FDA cleared and still be intentionally limited. The current 510(k) clearance for one report covers 44 selected BRCA1 and BRCA2 variants; a negative result does not exclude other disease-causing variants and does not establish average cancer risk. Clinical genetic testing starts with the reason for testing, personal and family history, appropriate genes and methods, a clinical laboratory, confirmation when needed, counseling, and a plan for relatives and medical follow-up.123
Do not rely on the obsolete shorthand that consumer testing covers only three variants. The exact device record, version, ancestry context, and variant list must be current.1
A selected-variant report and a clinical workup start in different places
| Decision field | Consumer selected-variant report | Clinical genetic pathway |
|---|---|---|
| Starting question | Does this sample contain one of the listed variants? | What inherited-risk question follows from history, diagnosis, or a relative's result? |
| Variant scope | Defined list in the clearance and report | Test design selected for the clinical question; may include sequencing, deletion/duplication or a multigene panel |
| Interpretation | Risk information and limitations supplied with the report | Variant classification integrated with history and current management guidance |
| Negative result | Listed variants were not detected | Residual risk depends on test scope, history, ancestry and what remains untested |
| Follow-up | Clinical confirmation and consultation may be recommended | Result disclosure, counseling, family implications and medical plan are built into the pathway |
FDA 510(k) clearance applies to the exact device and intended use in its decision record. It does not convert a limited report into comprehensive hereditary-cancer testing or authorize treatment based solely on the app screen.
Count variants, then inspect the method
Ask for the 510(k) number, current user guide, exact BRCA1/2 variant list, specimen, laboratory method, analytical performance, ancestry information, and limitations. “BRCA tested” is not a sufficient scope description.
A clinical test may sequence coding regions, examine selected intronic areas, assess large deletions or duplications, or include other genes. More genes are not automatically better; the panel should match the clinical question, and broader testing can increase uncertain or incidental findings.
The useful comparison is completeness for a defined purpose—not consumer versus doctor as a quality slogan.
A negative result has multiple meanings
If a known familial pathogenic variant was not tested, a negative consumer result may say little about that family’s question. If there is no known familial variant, residual risk still depends on family history, ancestry, genes and variants outside the report, and non-genetic factors.
The FDA decision summary explicitly warns that the selected-variant report is not an overall cancer-risk test and does not rule out other variants.1 Do not cancel established screening, ignore symptoms, or reassure relatives from a negative screen.
A clinical “negative” can also be uninformative if the tested person was not the most informative relative or the cause in a family is unknown. Genetic counseling helps define what was and was not answered.
Positive and uncertain findings need different handling
Before a medical decision, confirm whether the consumer result requires clinical confirmation, which sample and laboratory will be used, and how identity or sample-quality issues are handled. A pathogenic or likely pathogenic result, a variant of uncertain significance, and a raw-data interpretation are not interchangeable.
NCI explains that BRCA results affect risk discussions, relatives, surveillance and risk-reducing options in context.3 A variant of uncertain significance generally does not carry the same meaning as a pathogenic variant. Do not let a third-party raw-data upload silently change the classification or clinical plan.
Privacy is a separate consent decision
Read how the company stores the specimen and data, uses de-identified information, handles research consent, responds to legal requests, allows deletion, and shares with service providers. Health-information protections can differ between a consumer app and a clinician/laboratory relationship; HIPAA coverage depends on the entities and relationships involved.5
Privacy terms do not change analytical validity, and FDA clearance does not approve every business-data practice. Preserve a local copy of the original report even if the account is later closed.
The decisive question
Ask: “Which exact variants and methods did this test cover, what hereditary-risk question remains, and who owns confirmation, counseling, and medical follow-up?” A useful answer can explain both the value of the consumer result and its boundary.
Sources
- U.S. Food and Drug Administration. K223597 decision summary. Exact 510(k) clearance record for a consumer genetic health-risk report covering 44 selected BRCA1/BRCA2 variants and its limitations. Accessed .
- U.S. Food and Drug Administration. Direct-to-consumer tests. Federal overview of DTC test categories, review status, limitations, and follow-up. Accessed .
- National Cancer Institute. BRCA gene changes: cancer risk and genetic testing. Federal clinical overview of BRCA1/2 variants, risk, testing, counseling, and management context. Accessed .
- U.S. Preventive Services Task Force. BRCA-related cancer: risk assessment, genetic counseling, and genetic testing. Current update-in-progress source for risk-assessment and counseling boundaries; not treated as a final recommendation. Accessed .
- U.S. Department of Health and Human Services. The access right, health apps, & APIs. Current federal guidance explaining that HIPAA coverage depends on the relationship among the app, covered entity, and business associate. Accessed .